Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Regardless of whether a patient has localized or metastatic HCC, practitioners are able to deliver treatment to patients through the hepatic artery. Such therapies include chemotherapy and radiation therapy in order to maximize the potency but minimize toxicities.

View more from the 2016 School of Gastrointestinal Oncology

Jeff Geschwind, MD

Articles

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer